BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) Stock Fundamental Analysis
BIT:1BMRN - Euronext Milan - US09061G1013 - Common Stock - Currency: EUR
We assign a fundamental rating of 6 out of 10 to 1BMRN. 1BMRN was compared to 73 industry peers in the Biotechnology industry. 1BMRN has an excellent financial health rating, but there are some minor concerns on its profitability. 1BMRN is not priced too expensively while it is growing strongly. Keep and eye on this one! With these ratings, 1BMRN could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
1BMRN had positive earnings in the past year.
1BMRN had a positive operating cash flow in the past year.
In multiple years 1BMRN reported negative net income over the last 5 years.
In the past 5 years 1BMRN always reported a positive cash flow from operatings.
1.2 Ratios
1BMRN's Return On Assets of 4.70% is amongst the best of the industry. 1BMRN outperforms 80.82% of its industry peers.
1BMRN's Return On Equity of 5.95% is fine compared to the rest of the industry. 1BMRN outperforms 79.45% of its industry peers.
Looking at the Return On Invested Capital, with a value of 5.01%, 1BMRN belongs to the top of the industry, outperforming 83.56% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.7% | ||
| ROE | 5.95% | ||
| ROIC | 5.01% |
ROA(3y)1.2%
ROA(5y)3.56%
ROE(3y)1.65%
ROE(5y)5.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
1BMRN has a Profit Margin of 11.71%. This is amongst the best in the industry. 1BMRN outperforms 80.82% of its industry peers.
1BMRN's Profit Margin has declined in the last couple of years.
The Operating Margin of 1BMRN (14.88%) is better than 84.93% of its industry peers.
1BMRN has a Gross Margin of 78.95%. This is in the better half of the industry: 1BMRN outperforms 78.08% of its industry peers.
In the last couple of years the Gross Margin of 1BMRN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.88% | ||
| PM (TTM) | 11.71% | ||
| GM | 78.95% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-46.86%
PM growth 5YN/A
GM growth 3Y3.1%
GM growth 5Y-0.03%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so 1BMRN is destroying value.
The number of shares outstanding for 1BMRN has been increased compared to 1 year ago.
Compared to 5 years ago, 1BMRN has more shares outstanding
The debt/assets ratio for 1BMRN has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 5.66 indicates that 1BMRN is not in any danger for bankruptcy at the moment.
The Altman-Z score of 1BMRN (5.66) is better than 86.30% of its industry peers.
1BMRN has a debt to FCF ratio of 1.98. This is a very positive value and a sign of high solvency as it would only need 1.98 years to pay back of all of its debts.
The Debt to FCF ratio of 1BMRN (1.98) is better than 93.15% of its industry peers.
A Debt/Equity ratio of 0.11 indicates that 1BMRN is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.11, 1BMRN is doing good in the industry, outperforming 67.12% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 1.98 | ||
| Altman-Z | 5.66 |
ROIC/WACC0.55
WACC9.04%
2.3 Liquidity
1BMRN has a Current Ratio of 4.27. This indicates that 1BMRN is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of 1BMRN (4.27) is better than 76.71% of its industry peers.
A Quick Ratio of 2.62 indicates that 1BMRN has no problem at all paying its short term obligations.
With a decent Quick ratio value of 2.62, 1BMRN is doing good in the industry, outperforming 67.12% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.27 | ||
| Quick Ratio | 2.62 |
3. Growth
3.1 Past
1BMRN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 127.27%, which is quite impressive.
The earnings per share for 1BMRN have been decreasing by -40.67% on average. This is quite bad
Looking at the last year, 1BMRN shows a quite strong growth in Revenue. The Revenue has grown by 19.14% in the last year.
The Revenue has been growing by 10.16% on average over the past years. This is quite good.
EPS 1Y (TTM)127.27%
EPS 3Y-40.67%
EPS 5YN/A
EPS Q2Q%161.9%
Revenue 1Y (TTM)19.14%
Revenue growth 3Y9.15%
Revenue growth 5Y10.16%
Sales Q2Q%28.29%
3.2 Future
The Earnings Per Share is expected to grow by 49.08% on average over the next years. This is a very strong growth
Based on estimates for the next years, 1BMRN will show a quite strong growth in Revenue. The Revenue will grow by 11.86% on average per year.
EPS Next Y120.5%
EPS Next 2Y79.23%
EPS Next 3Y62.26%
EPS Next 5Y49.08%
Revenue Next Year17.05%
Revenue Next 2Y13.38%
Revenue Next 3Y12.22%
Revenue Next 5Y11.86%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 33.78, 1BMRN can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of 1BMRN indicates a rather cheap valuation: 1BMRN is cheaper than 83.56% of the companies listed in the same industry.
1BMRN's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 26.17.
Based on the Price/Forward Earnings ratio of 19.42, the valuation of 1BMRN can be described as rather expensive.
Based on the Price/Forward Earnings ratio, 1BMRN is valued cheaper than 87.67% of the companies in the same industry.
1BMRN's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.10.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.78 | ||
| Fwd PE | 19.42 |
4.2 Price Multiples
76.71% of the companies in the same industry are more expensive than 1BMRN, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, 1BMRN is valued cheaper than 80.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 37.54 | ||
| EV/EBITDA | 20.26 |
4.3 Compensation for Growth
1BMRN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
1BMRN has a very decent profitability rating, which may justify a higher PE ratio.
1BMRN's earnings are expected to grow with 62.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.28
PEG (5Y)N/A
EPS Next 2Y79.23%
EPS Next 3Y62.26%
5. Dividend
5.1 Amount
No dividends for 1BMRN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIT:1BMRN (5/19/2025, 7:00:00 PM)
52.36
-9.36 (-15.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap9.98B
Analysts78.86
Price Target93.14 (77.88%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.72%
Min EPS beat(2)4.22%
Max EPS beat(2)57.23%
EPS beat(4)3
Avg EPS beat(4)16.93%
Min EPS beat(4)-24.46%
Max EPS beat(4)57.23%
EPS beat(8)6
Avg EPS beat(8)28.16%
EPS beat(12)9
Avg EPS beat(12)-8.43%
EPS beat(16)13
Avg EPS beat(16)29.42%
Revenue beat(2)2
Avg Revenue beat(2)4.93%
Min Revenue beat(2)4.42%
Max Revenue beat(2)5.44%
Revenue beat(4)2
Avg Revenue beat(4)1.73%
Min Revenue beat(4)-2.4%
Max Revenue beat(4)5.44%
Revenue beat(8)3
Avg Revenue beat(8)-0.1%
Revenue beat(12)5
Avg Revenue beat(12)-0.4%
Revenue beat(16)8
Avg Revenue beat(16)0.27%
PT rev (1m)-8.29%
PT rev (3m)-8.29%
EPS NQ rev (1m)8.71%
EPS NQ rev (3m)8.71%
EPS NY rev (1m)7.83%
EPS NY rev (3m)7.83%
Revenue NQ rev (1m)-3.34%
Revenue NQ rev (3m)-3.34%
Revenue NY rev (1m)2.75%
Revenue NY rev (3m)2.75%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.78 | ||
| Fwd PE | 19.42 | ||
| P/S | 4.1 | ||
| P/FCF | 37.54 | ||
| P/OCF | 27.23 | ||
| P/B | 2.09 | ||
| P/tB | 2.28 | ||
| EV/EBITDA | 20.26 |
EPS(TTM)1.55
EY2.96%
EPS(NY)2.7
Fwd EY5.15%
FCF(TTM)1.39
FCFY2.66%
OCF(TTM)1.92
OCFY3.67%
SpS12.76
BVpS25.1
TBVpS22.98
PEG (NY)0.28
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.7% | ||
| ROE | 5.95% | ||
| ROCE | 6.68% | ||
| ROIC | 5.01% | ||
| ROICexc | 5.9% | ||
| ROICexgc | 6.47% | ||
| OM | 14.88% | ||
| PM (TTM) | 11.71% | ||
| GM | 78.95% | ||
| FCFM | 10.93% |
ROA(3y)1.2%
ROA(5y)3.56%
ROE(3y)1.65%
ROE(5y)5.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-46.86%
PM growth 5YN/A
GM growth 3Y3.1%
GM growth 5Y-0.03%
F-Score8
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 1.98 | ||
| Debt/EBITDA | 1.17 | ||
| Cap/Depr | 114.17% | ||
| Cap/Sales | 4.14% | ||
| Interest Coverage | 39.55 | ||
| Cash Conversion | 81.42% | ||
| Profit Quality | 93.35% | ||
| Current Ratio | 4.27 | ||
| Quick Ratio | 2.62 | ||
| Altman-Z | 5.66 |
F-Score8
WACC9.04%
ROIC/WACC0.55
Cap/Depr(3y)114.13%
Cap/Depr(5y)125.65%
Cap/Sales(3y)5.73%
Cap/Sales(5y)6.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)127.27%
EPS 3Y-40.67%
EPS 5YN/A
EPS Q2Q%161.9%
EPS Next Y120.5%
EPS Next 2Y79.23%
EPS Next 3Y62.26%
EPS Next 5Y49.08%
Revenue 1Y (TTM)19.14%
Revenue growth 3Y9.15%
Revenue growth 5Y10.16%
Sales Q2Q%28.29%
Revenue Next Year17.05%
Revenue Next 2Y13.38%
Revenue Next 3Y12.22%
Revenue Next 5Y11.86%
EBIT growth 1Y243.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year193.21%
EBIT Next 3Y78.73%
EBIT Next 5Y49.65%
FCF growth 1Y639.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y130.12%
OCF growth 3Y23.09%
OCF growth 5Y51.13%